Literature DB >> 32267313

Uninterrupted Direct Oral Anticoagulants in Atrial Fibrillation Catheter Ablation: Ready for Prime Time.

Rhanderson Cardoso1, André D'Avila2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32267313      PMCID： PMC7792720          DOI： 10.36660/abc.20200110

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN： 0066-782X            Impact factor:   2.000


× No keyword cloud information.
  8 in total

1.  Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.

Authors:  Hugh Calkins; Stephan Willems; Edward P Gerstenfeld; Atul Verma; Richard Schilling; Stefan H Hohnloser; Ken Okumura; Harvey Serota; Matias Nordaby; Kelly Guiver; Branislav Biss; Marc A Brouwer; Massimo Grimaldi
Journal:  N Engl J Med       Date:  2017-03-19       Impact factor: 91.245

Review 2.  An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.

Authors:  Rhanderson Cardoso; Leonardo Knijnik; Aditya Bhonsale; Jared Miller; Guilherme Nasi; Manuel Rivera; Vanessa Blumer; Hugh Calkins
Journal:  Heart Rhythm       Date:  2017-09-14       Impact factor: 6.343

Review 3.  Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.

Authors:  Rhanderson Cardoso; Stephan Willems; Edward P Gerstenfeld; Atul Verma; Richard Schilling; Stefan H Hohnloser; Ken Okumura; Matias Nordaby; Marc A Brouwer; Hugh Calkins
Journal:  Clin Cardiol       Date:  2018-12-07       Impact factor: 2.882

4.  Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.

Authors:  Akihiko Nogami; Tomoo Harada; Yukio Sekiguchi; Ryuji Otani; Yukihiko Yoshida; Kentaro Yoshida; Yukiko Nakano; Norihito Nuruki; Shiro Nakahara; Masahiko Goya; Hideki Origasa; Yasuki Kihara; Kenzo Hirao; Kazutaka Aonuma
Journal:  JAMA Netw Open       Date:  2019-04-05

5.  Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.

Authors:  Luigi Di Biase; J David Burkhardt; Pasquale Santangeli; Prasant Mohanty; Javier E Sanchez; Rodney Horton; G Joseph Gallinghouse; Sakis Themistoclakis; Antonio Rossillo; Dhanunjaya Lakkireddy; Madhu Reddy; Steven Hao; Richard Hongo; Salwa Beheiry; Jason Zagrodzky; Bai Rong; Sanghamitra Mohanty; Claude S Elayi; Giovanni Forleo; Gemma Pelargonio; Maria Lucia Narducci; Antonio Dello Russo; Michela Casella; Gaetano Fassini; Claudio Tondo; Robert A Schweikert; Andrea Natale
Journal:  Circulation       Date:  2014-04-17       Impact factor: 29.690

6.  Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.

Authors:  Riccardo Cappato; Francis E Marchlinski; Stefan H Hohnloser; Gerald V Naccarelli; Jim Xiang; David J Wilber; Chang-Sheng Ma; Susanne Hess; Darryl S Wells; George Juang; Johan Vijgen; Burkhard J Hügl; Richard Balasubramaniam; Christian De Chillou; D Wyn Davies; L Eugene Fields; Andrea Natale
Journal:  Eur Heart J       Date:  2015-05-14       Impact factor: 29.983

7.  Figure-of-eight suture for venous hemostasis in fully anticoagulated patients after atrial fibrillation catheter ablation.

Authors:  Umashankar Lakshmanadoss; Wai Shun Wong; Ilana Kutinsky; M Rizwan Khalid; Brian Williamson; David E Haines
Journal:  Indian Pacing Electrophysiol J       Date:  2017-02-20

8.  Safety of Catheter Ablation of Atrial Fibrillation Under Uninterrupted Rivaroxaban Use.

Authors:  Márcio Augusto Silva; Guilherme Muller de Campos Futuro; Erick Sessa Merçon; Deborah Vasconcelos; Rovana Silva Agrizzi; Jorge Elias Neto; Ricardo Kuniyoshi
Journal:  Arq Bras Cardiol       Date:  2020-03       Impact factor: 2.000
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.